Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Protalex SpA Treatment For Rheumatoid Arthritis Could Be A Blockbuster

Protalex, Inc. (OTCQB:PRTX) is developing PRTX-100, a highly purified form of the bacterial protein Staphylococcal protein A (SpA) as a treatment for rheumatoid arthritis and other autoimmune disorders. We believe the company has significant upside potential provided that the safety and efficacy seen in its early clinical trials of PRTX-100 in rheumatoid arthritis (RA) patients holds up on testing in larger numbers of patients in later-stage studies. We believe the shares are worth $3.50.

Rheumatoid Arthritis Background Info

Rheumatoid arthritis is a chronic, systematic, autoimmune inflammatory disease that manifests as joint pain, stiffness, and swelling. Peripheral joints, including the wrists, hands, shoulders, elbows, hips, knees, and ankles are most commonly affected, with a bilaterally symmetric distribution of relapsing

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details